News | June 17, 2024
Devyser announces expanded commercial agreement with Thermo Fisher Scientific for post-transplant monitoring NGS products
Find out more
Admin (3)
Devyser wins all-time high tender for up to 75 MSEK
.png)
Devyser wins tender for oncology NGS solutions in Italy
Devyser wins tender for thalassemia in Italy
Devyser Diagnostics AB publishes quarterly report for the period January to March 2024
.png)
Devyser receives IVDR approval for post-transplant monitoring software
Devyser partners with Hamilton to automate laboratory NGS workflows
Devyser receives MDSAP certification for Brazil
Devyser publishes annual report for 2023
Devyser´s annual report 2023 has today been published on the company´s website. The report is...
-1.png)
Devyser CFTR 68 provides NHS Scotland with trustworthy, rapid results
We spoke with Dr. Andrew Purvis, Clinical Scientist for West of Scotland Centre for Genomic...
-2.png)
Devyser achieves breakthrough in the US with cystic fibrosis NGS test
Devyser has secured a CFTR NGS proposal with UNC Hospitals. The proposal with UNC Hospitals is...
2023: A year in studies
2023 was an excellent year for Devyser, and a range of our products appeared in scientific journals...